India’s pharmaceutical sector experienced a notable 12.1% growth in July, buoyed by gains in chronic-care medicines and standout performances by mid-sized companies, signalling a resilient recovery and expanding footprint in the healthcare sector.
India’s pharmaceutical market grew 12.1% in July, reaching ₹23,193 crore, as almost every major therapy posted gains, according to market research firm Pharmarack. That was up from ₹20,494 crore a year earlier and pointed to a broad-based recovery in domestic demand, with chronic-care medicines doing much of the heavy lifting.
Cardiac and anti-diabetic treatments led the advance. Pharmarack said cardiac sales rose 14.7% to ₹3,299 crore, while anti-diabetic medicines increased 17.6% to ₹2,237 crore. Sheetal Sapale, vice-president for commercial at Pharmarack, said the anti-diabetic segment was supported by the large burden of hypertension and type 2 diabetes, along with steady growth in GLP-1 drugs used to control blood sugar. Anti-infectives also gained 6.2% as the monsoon season brought more flu cases, while gastrointestinal medicines rose 9.2% to ₹2,820 crore.
Together, those four therapy areas accounted for 46.6% of the Indian pharmaceutical market in July, Pharmarack said. The market’s moving annual turnover, covering August 2025 to July 2026, grew 10.2% to ₹2.56 trillion. That fits a broader pattern of resilience in 2026: Pharmabiz reported that the market posted 13.3% value growth in June and said Pharmarack expects full-year growth of 11.3% by December 2026.
Among companies, the largest players recorded only modest monthly gains, but several mid-sized manufacturers outperformed the market. Pharmarack said Zydus grew 20.8% in July, Sun Pharma 17.8%, Torrent 16.1% and Intas 14.9%. The results come after a 2025 base that was already firm, with IBEF reporting 7.9% growth in July last year, suggesting the sector’s recent strength is being reinforced by both chronic demand and sustained product expansion.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
